Abstracts tagged "Disease Activity"

Abstract Number: 2913 • 2014 ACR/ARHP Annual Meeting
Does Corticosteroid Therapy at Disease Onset Influence Disease Progression of RA? Results from the Swiss Prospective Observational Cohort
Ruediger Mueller¹, Nazim Reshiti², Toni Kaegi³, Axel Finckh⁴, Hendrik Schulze-Koops⁵, Michael H. Schiff⁶ and Johannes von Kempis⁷, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, St. Gallen, Switzerland, ³Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ⁶School of Medicine, University of Colorado, Denver, CO, ⁷Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland
Background/Purpose Anti-inflammatory and disease-modifying properties of glucocorticoids (GCs) have been demonstrated in patients with rheumatoid arthritis (RA). Better outcomes in trials by combinations of synthetic…
Abstract Number: 2518 • 2014 ACR/ARHP Annual Meeting
What Is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors?
Edward C. Keystone¹, Philip Baer², J. Antonio Avina-Zubieta³, Anna Jaroszynska⁴, Jude Rodrigues⁵, Regan Arendse⁶, Dalton Sholter⁷, Michael Starr⁸, Ariel Masetto⁹, John S. Sampalis¹⁰, Emmanouil Rampakakis¹⁰, Francois Nantel¹¹, May Shawi¹¹, Allen J Lehman¹² and Susan Otawa¹², ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Private Practice, Scarborough, ON, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Private Practice, Burlington, ON, Canada, ⁵Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷University of Alberta, Edmonton, AB, Canada, ⁸Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁹Rheumatology, CHUS, Fleurimont, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Several standardized response criteria and disease activity indices are used to assess treatment efficacy in rheumatoid arthritis (RA). These measures comprise different types and…
Abstract Number: 2145 • 2014 ACR/ARHP Annual Meeting
Diagnostic Performance and Disease Activity Assessment By FDG-PET in Large-Vessel Vasculitis: A Systematic Literature Review and Meta-Analysis
Michael Soussan¹, Patrick Nicolas², Catherine Schramm³, Sandrine Katsahian³, Veronique Eder⁴, Olivier Fain⁵ and Arsene Mekinian⁶, ¹Nuclear Medicine, Avicennes Hospital, Bobigny, France, ²Pharmacology, Avicenne Hospital, 93000, France, ³Inserm U1138, Centre de Recherche des Cordeliers, Equipe 22, Paris 5, Paris 6, Paris, France, paris, France, ⁴Nuclear Medicine, Avicenne Hospital, Bobigny, France, ⁵Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, ⁶Internal Medicine, DHUi2B Saint Antoine Hospital, paris, France
Background/Purpose: FDG-PET is increasingly used in the work up of large-vessel vasculitis (LVV). The purpose of this study is to perform a systematic review and…
Abstract Number: 1584 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Patient Acceptable Symptom State in Patients with Psoriatic Arthritis
Pinar Cetin¹, Dilek Solmaz², Murat Keser³, Ismail Sari¹, Merih Birlik¹, Nurullah Akkoc¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Namik Kemal University School of Medicine, Tekirdag, Turkey, ³Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey
Background/Purpose The Patient Acceptable Symptom State (PASS), a single-question outcome, has been defined as an absolute level of patient well-being, which was used in the…
Abstract Number: 1238 • 2014 ACR/ARHP Annual Meeting
Proportion of Peripheral Plasmacytoid Dendritic Cells and Plasmablasts Reflects Disease Activity in IgG4-related Disease
Mitsuhiro Akiyama¹, Katsuya Suzuki¹, Yoshiaki Kassai², Takahiro Miyazaki², Rimpei Morita³, Akihiko Yoshimura³ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ³Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Immunoglobulin (Ig) G4-related disease (IgG4-RD) is a recently recognized fibro-inflammatory disease with multi-organ system involvement. Affected patients frequently have a history of bronchial asthma and allergic rhinitis. The reported pathogenesis of IgG4-RD describes the clear involvement of excessive Th2 cells and regulatory immune reaction in addition to plasma cells 1). However, peripheral immune cell phenotype, which reflects disease status, has not been comprehensively evaluated. Our aim was to definitively determine peripheral blood cell abnormalities and their correlation with disease activity in patients with IgG4-RD.Methods Peripheral blood samples were obtained from active untreated IgG4-RD patients (n=11) and healthy controls (n=16). Comprehensive immunophenotyping assay with information on activation status was done by multi-color flow cytometry, and the proportion of peripheral blood mononuclear cells (PBMCs), including T cells (naïve/memory, Th1/2/17, Treg, and Tfh), B cells (naïve/memory, plasmablast, Breg), monocytes (classical, intermediate, non-classical) and dendritic cells (myeloid, plasmacytoid), and their activity status were precisely defined. Disease activity was measured using the IgG4-RD responder index (RI). Statistical analysis was done using the Mann-Whitney U test and Spearman rank correlation coefficient test.Results The proportion of plasmablasts (CD19+CD20-CD27+CD38+), memory Th2 cells (CD3+CD4+CXCR3-CCR6-CD45RA-), Tregs (CD3+CD4+CD25+CD127low), Tfh (CD3+CD4+CXCR5+), and mDCs (CD3-CD19-CD14-HLA-DR+CD1c+CD303-) in peripheral blood was significantly increased in IgG4-RD patients compared with HC, whereas the proportion of pDCs (CD3-CD19-CD14-HLA-DR+CD1c-CD303+）was significantly decreased. Interestingly, the proportion of pDCs in total DCs was negatively correlated with IgG4-RD RI (r=-0.778, p=0.005) while the proportion of plasmablasts in CD19+cells was positively correlated with RI (r=0.701, p=0.016). Further, the increased proportion of plasmablasts was positively correlated with serum IgG4 level (r=0.718, p=0.013) while the decreased proportion of pDCs tended to be negatively correlated with the number of affected organs (r=-0.518, p=0.061). Conclusion Our comprehensive analysis identified distinct proportional changes in PBMCs in IgG4-RD. In particular, the decrease in pDCs and increase in plasmablasts were strongly linked with disease activity. These combined measurements are expected to be clinically useful surrogate cell markers. This newly identified decrease in circulating pDCs may be involved in the pathogenesis in IgG4-RD via the recently described role in the enhancement of Th2 response 2).References: 1) Stone JH et.al. N Engl J Med 2012;366:539-51 2) Maazi H et.al. Allergy 2013;68:695-701
Abstract Number: 720 • 2014 ACR/ARHP Annual Meeting
Measures of Disease Status in Systemic Sclerosis: Systematic Review
Tien Tay¹, Nava Ferdowsi¹, Wendy Stevens¹, Marie Hudson², Murray Baron³, Candice Rabusa¹, David Prior⁴, Susanna Proudman⁵ and Mandana Nikpour⁶, ¹Rheumatology, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ²Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁴Cardiology, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ⁵Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁶Medicine, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia
Background/Purpose : To identify the measures of disease status in systemic sclerosis (SSc) using a systematic review. Methods: A systematic review of Medline (1966-2014), EMBASE…
Abstract Number: 426 • 2014 ACR/ARHP Annual Meeting
Exploring the DAS: What Is the Level of Agreement in the Classification of Remission and Low Disease Activity (LDA) Among the Various Versions of the Disease Activity Score (DAS) and Their Correlation? an Analysis from a Prospective, Observational Registry
WG Bensen¹, Edward Keystone², Philip Baer³, Jude Rodrigues⁴, J. Antonio Avina-Zubieta⁵, Wojciech Olszynski⁶, Denis Choquette⁷, Suneil Kapur⁸, Manisha Mulgund⁹, John S. Sampalis¹⁰, Emmanouil Rampakakis¹⁰, Francois Nantel¹¹, Allen J Lehman¹², May Shawi¹¹ and Susan Otawa¹², ¹St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Private Practice, Scarborough, ON, Canada, ⁴Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁸Rheumatology, University of Ottawa, Ottawa, ON, Canada, ⁹Private Practice, Hamilton, ON, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Two versions of DAS28 are available, DAS28-4 comprising 4 variables [tender and swollen joint counts, acute phase reactant (APR), and patient global assessment] and…
Abstract Number: 350 • 2014 ACR/ARHP Annual Meeting
Rho-Associated Protein Kinase (ROCK) Activity Is Elevated in Rheumatoid Arthritis (RA) Patients and May be Responsive to RA Therapies
Reena Khianey¹, Cristina Rozo², Sanjay Gupta³, Vivian P. Bykerk¹, Susan M. Goodman¹ and Alessandra B. Pernis⁴, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²535 East 70th Street, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Research, Hospital for Special Surgery, New York, NY
Background/Purpose: Rho-associated protein kinases (ROCKs) regulate cytoskeletal reorganization and gene expression through protein phosphorylation, and are implicated in the pathogenesis of a wide range of…
Abstract Number: 2890 • 2014 ACR/ARHP Annual Meeting
Does a Family History of RA Influence the Clinical Presentation and Treatment Response in RA?
Thomas Frisell¹, Saedis Saevarsdottir^2,3 and Johan Askling^1,4, ¹Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Since family history of RA is among the strongest risk factors for developing the disease, individuals suspected to have RA are routinely asked about…
Abstract Number: 2517 • 2014 ACR/ARHP Annual Meeting
Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders
Josef Smolen¹, Ronald F. van Vollenhoven², Stefan Florentinus³, Yijie Zhou⁴, Benoit Guerette⁴ and Arthur Kavanaugh⁵, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³AbbVie, Rungis, France, ⁴AbbVie, Inc., North Chicago, IL, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Methotrexate (MTX) is used as first line therapy for treatment of rheumatoid arthritis (RA). Current recommendations state that therapy should be adjusted if patients…
Abstract Number: 2126 • 2014 ACR/ARHP Annual Meeting
The Utility of Digital Activity Fluorescence Optical Imaging in Quantifying Hand and Wrist Inflammation in Rheumatic Diseases
Yogan Kisten¹, Noémi Györi¹, Hamed Rezaei^2,3, Adrian Levitsky⁴, Anna Karlsson¹, Erik af Klint³ and Ronald van Vollenhoven^3,5, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The rheumatology clinic of the Karolinska University Hospital, Stockholm, Sweden, ⁴The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, ⁵Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose The objective detection and quantification of disease activity in its earliest pathophysiological stage is critical for achieving optimal therapy results. Fluorescence optical imaging (FOI)…
Abstract Number: 1577 • 2014 ACR/ARHP Annual Meeting
Value and Prediction of Minimal Disease Activity in Patients with Psoriatic Arthritis
Arthur Kavanaugh¹, Philip J. Mease², Laura C. Coates³, Iain B. McInnes⁴, Maja Hojnik⁵, Alex Dorr⁶, Ying Zhang⁶, Benoit Guerette⁶, Alan Friedman⁶ and Dafna D. Gladman⁷, ¹University of California San Diego, La Jolla, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁵AbbVie, Ljubljana, Slovenia, ⁶AbbVie, Inc., North Chicago, IL, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose The prediction of treatment outcomes based on early response could be useful in guiding decisions to adjust therapy. The objective was to determine if…
Abstract Number: 1147 • 2014 ACR/ARHP Annual Meeting
Economic Implications of Flares Among Patients with Early Rheumatoid Arthritis (RA)
James Signorovitch¹, Keith Betts¹, Vishvas Garg² and Yanjun Bao², ¹Analysis Group, Inc., Boston, MA, ²AbbVie Inc., North Chicago, IL
Background/Purpose: Government mandated dose tapering and withdrawal of biologic treatments for RA after achievement of sustained disease control is currently observed in Taiwan, the Netherlands,…
Abstract Number: 701 • 2014 ACR/ARHP Annual Meeting
How Important Is Physical Activity for Patients with Systemic Lupus Erythematodes? -Results of Lula-Study
Isabelle Kloubert¹, Gamal Chehab¹, Jutta Richter², Rebecca Fischer-Betz³, Ralph Brinks² and Matthias Schneider¹, ¹Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ³Department of Rheumatology, University of Düsseldorf, Düsseldorf, Germany
Background/Purpose Physical activity (PA) plays a decisive role in primary and secondary prevention in various domains of medicine. Our examination aimed to determine association PA…
Abstract Number: 422 • 2014 ACR/ARHP Annual Meeting
Correlation of RAPID3, DAS28 and CDAI in Disease Activity and Effects of Education Level and Co-Morbid Diseases on This Assesment in RA
Kubilay Sahin¹, Yasar Karaaslan^2,3, Zeynep Ozbalkan¹, Ahmet Omma¹ and Nesibe Yesil¹, ¹Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey, ²Rheumatology, Hitit University, Corum, Turkey, ³Ankara Numune Training and Research Hospital, Ankara, Turkey
Background/Purpose RAPID3 is an activity index based on only the patient's report in RA. It doesn’t require joint counts and it isn’t time consuming. Therefore…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].